Cinchona is a tropical tree whose bark produces quinine and several related compounds that have been used to treat malaria for nearly 400 years. Today, cinchona bark is primarily harvested for the food and beverage industry, with 300 to 500 tons of quinine produced annually from plantations in Africa. It also remains a source of quinidine, a compound used to treat abnormal heart rhythms.
How Cinchona Became the World’s First Malaria Drug
Indigenous people in the Andes chewed cinchona bark, which they called quina-quina, to stop shivering at high altitudes. When Spanish Jesuits encountered malaria patients shaking with chills in colonial Peru, they reasoned the bark might work for that too. By the early 1630s, historical records show the Viceroy of Peru fell ill with malaria and was cured with cinchona bark powder. The bark began arriving in Europe in the late 1620s and early 1630s, reaching Spain and then Italy, and by 1647 it was flowing continuously into Rome.
Carl Linnaeus formally identified the species as Cinchona officinalis in 1735. Over the following centuries, European colonial powers established massive plantations to secure their own supply. During World War II, large cinchona plantations were built across Africa. By 1998, what was then Zaire (now the Democratic Republic of Congo) had become the world’s top supplier, with additional production in Burundi, Cameroon, and Kenya. Limited cultivation continues in South America, Indonesia, and India.
Treating Malaria
Cinchona’s bark contains four primary alkaloids: quinine, quinidine, cinchonine, and cinchonidine. All four share a similar chemical backbone, but quinine and quinidine are the most medically significant. These compounds kill malaria parasites by interfering with how the parasite processes hemoglobin inside red blood cells. Normally, the parasite breaks down hemoglobin and converts the toxic byproduct (free heme) into a harmless crystal. Quinine blocks that conversion, causing free heme to accumulate. The buildup triggers a cascade of oxidative damage that destroys the parasite from within.
For most of modern history, quinine was the only reliable treatment for malaria. That changed with the development of newer combination therapies called ACTs (artemisinin-based combination therapies), which are now the standard of care worldwide. The World Health Organization updated its guidelines in 2022 to recommend ACTs even for pregnant women in their first trimester, a group that had previously been treated with a seven-day course of quinine plus an antibiotic. The shift happened because ACTs proved more effective and caused fewer adverse pregnancy outcomes. Quinine still has a role in severe malaria cases or in settings where ACTs are unavailable, but it is no longer the first-choice treatment in most situations.
Heart Rhythm Disorders
Quinidine, the second major alkaloid in cinchona bark, is an FDA-approved medication for several cardiac conditions. It works by slowing the electrical signals that coordinate heartbeats, specifically by blocking sodium channels in heart muscle cells. This makes it useful for converting atrial fibrillation or atrial flutter back to a normal rhythm, reducing the frequency of those episodes, and suppressing dangerous ventricular arrhythmias.
Quinidine is one of the oldest drugs still used for heart rhythm management. It remains particularly valuable for treating rare but serious conditions like Brugada syndrome, early repolarization syndrome, and idiopathic ventricular fibrillation, where newer antiarrhythmic drugs may not be effective.
Tonic Water and the Beverage Industry
The bulk of cinchona bark harvested today goes not to pharmacies but to beverage manufacturers. Quinine is an FDA-approved flavoring agent that gives tonic water its characteristic bitter taste. Federal regulations cap quinine in carbonated beverages at 83 parts per million, a concentration far too low to have any medicinal effect. An estimated 5,000 to 10,000 tons of raw bark are processed each year to produce the 300 to 500 tons of quinine used mainly by the food industry.
Cinchona bark also appears as a bittering agent in some amari, vermouth, and other cocktail bitters. Its intensely bitter flavor profile makes it a natural fit for drinks designed around that taste.
Leg Cramps: A Controversial Use
For decades, doctors prescribed low-dose quinine sulfate (200 to 300 mg at bedtime) for nocturnal leg cramps. Two systematic reviews found it modestly effective, reducing cramp frequency by about 25%, cramp intensity by about 10%, and the number of days with cramps by about 20%. Those benefits, however, come with real risks. Even at standard doses, quinine can cause tinnitus, hearing loss, visual disturbances, nausea, dizziness, and low blood sugar. More concerning are rare but serious blood disorders, including immune-related destruction of platelets.
In 2009, the FDA explicitly stated that quinine has an unfavorable risk-benefit ratio when used for leg cramps. It is no longer approved for that purpose in the United States, though some clinicians still prescribe it in carefully selected cases where other options have failed.
Cinchonism: Signs of Toxicity
Quinine has a relatively narrow margin between a therapeutic dose and a toxic one. The classic toxicity syndrome, called cinchonism, typically appears within three to six hours of ingestion. Early symptoms include nausea, abdominal pain, vomiting, diarrhea, headache, sweating, ringing in the ears, and hearing loss. These symptoms are usually reversible.
More severe poisoning shows up 6 to 15 hours after ingestion, starting with blurred vision and disturbed color perception. At plasma concentrations above 15 mg/L, the risk of permanent vision damage and dangerous heart rhythm changes rises significantly. At its worst, quinine toxicity can cause seizures, kidney failure, dangerously low blood sugar, and cardiac arrest. This toxicity profile is one reason quinine has been steadily replaced by safer alternatives for most of its former uses.
Traditional Uses Beyond Malaria
Cinchona bark has a long history as a general fever reducer and digestive bitter. Its intensely bitter compounds stimulate saliva and gastric acid production, which is why herbalists and traditional practitioners have used it as an appetite stimulant and digestive aid. In traditional European herbal medicine, cinchona was classified as a “febrifuge,” a substance that lowers fever, and was used for febrile illnesses well beyond malaria. These traditional uses laid the groundwork for cinchona’s modern role as a bittering agent in food and drinks, even as its medicinal applications have narrowed to specific clinical situations.